Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Non Operating Income (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Non Operating Income for 15 consecutive years, with $190000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 35.71% to $190000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 million, a 49.8% decrease, with the full-year FY2025 number at -$512000.0, down 158.85% from a year prior.
  • Non Operating Income was $190000.0 for Q4 2025 at Aytu Biopharma, down from $201000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $3.7 million in Q2 2023 to a low of -$1.2 million in Q4 2022.
  • A 5-year average of $750263.2 and a median of $463000.0 in 2022 define the central range for Non Operating Income.
  • Biggest YoY gain for Non Operating Income was 2867.5% in 2022; the steepest drop was 377.82% in 2022.
  • Aytu Biopharma's Non Operating Income stood at -$257000.0 in 2021, then tumbled by 377.82% to -$1.2 million in 2022, then soared by 107.82% to $96000.0 in 2023, then soared by 45.83% to $140000.0 in 2024, then skyrocketed by 35.71% to $190000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Non Operating Income are $190000.0 (Q4 2025), $201000.0 (Q3 2025), and $1.3 million (Q2 2025).